<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background </plain></SENT>
<SENT sid="1" pm="."><plain>The outcome of HIV-associated non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) has improved substantially in the highly active antiretroviral therapy (HAART) era </plain></SENT>
<SENT sid="2" pm="."><plain>However, HIV-Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), which accounts for up to 20% of HIV-NHL, has poor outcome with standard chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>Patients and Methods </plain></SENT>
<SENT sid="4" pm="."><plain>We retrospectively reviewed HIV-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> treated in the HAART era with the Magrath regimen (CODOX-M/IVAC±R) at four Canadian centres </plain></SENT>
<SENT sid="5" pm="."><plain>Results </plain></SENT>
<SENT sid="6" pm="."><plain>Fourteen patients with HIV-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> received at least one CODOX-M/IVAC±R treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Median age at <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> diagnosis was 45.5 years, CD4 count 375 cells/mL and HIV <z:mp ids='MP_0001799'>viral</z:mp> load (VL) &lt;50 copies/mL </plain></SENT>
<SENT sid="8" pm="."><plain>Patients received <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCP</z:e> prophylaxis and G-CSF, 13 received HAART with chemotherapy and 10 rituximab </plain></SENT>
<SENT sid="9" pm="."><plain>There were 63 episodes of toxicity, none fatal, including: <z:mp ids='MP_0001794'>bacterial</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, n = 20; grade 3-4 hematologic toxicity, n = 14; febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, n = 7; <z:e sem="disease" ids="C0006849" disease_type="Disease or Syndrome" abbrv="">oral thrush</z:e>; and ifosfamide neurological toxicity, n = 1 each </plain></SENT>
<SENT sid="10" pm="."><plain>At a median followup of 11.7 months, 12 (86%) patients are alive and in remission </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 10 patients who received HAART, chemotherapy, and rituximab are alive </plain></SENT>
<SENT sid="12" pm="."><plain>CD4 counts and HIV VL 6 months following <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> therapy completion (n = 5 patients) were &gt;250 cells/mL and undetectable, respectively, in 4 </plain></SENT>
<SENT sid="13" pm="."><plain>Conclusion </plain></SENT>
<SENT sid="14" pm="."><plain>Intensive chemotherapy with CODOX-M/IVAC±R yielded acceptable toxicity and good survival rates in patients with HIV-associated Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> receiving HAART </plain></SENT>
</text></document>